<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03203590</url>
  </required_header>
  <id_info>
    <org_study_id>3939366</org_study_id>
    <nct_id>NCT03203590</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients</brief_title>
  <official_title>Oral Navelbine Carboplatin Versus Gefitinib Neoadjuvant Therapy for Resectable EGFR Mutation Positive Stage Ⅱ-ⅢA NSCLC, Prospective, Randomized, Multicenter, Phase Ⅲ Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shenzhen People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dongguan People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maoming Affiliated Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficiency and safety of Gefitinib Neoadjuvant
      Therapy and Oral Navelbine Carboplatin Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢA NSCLC
      patients with EGFR mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancer is the most common cause of cancer mortality in men and women in the world. LACE
      meta analysis shows that the 5-year survival rate of post-operation chemotherapy group rose
      by 5.4%, therefore, adjuvant chemotherapy has been the main treatment after surgery according
      to National Comprehensive Cancer Network (NCCN) Guideline. But patients have poor compliance
      due to physical condition after surgery. Compared with adjuvant chemotherapy, neoadjuvant
      therapy has better patient compliance and tolerance.Targeted therapy, with milder side effect
      compared with chemotherapy, may be a promising choice to treat NSCLC previously. But to date,
      there is no enough evidence to support the efficacy and safety of neoadjuvant targeted
      therapy in patients with EGFR mutation.The purpose of this study is to evaluate the
      efficiency and safety of Gefitinib Neoadjuvant Therapy vs Oral Navelbine Carboplatin
      Neoadjuvant Therapy for Resectable NSCLC patients harboring EGFR mutation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year disease free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>1 week before surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete response</measure>
    <time_frame>Within 1 month after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>1 week before surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard uptake value</measure>
    <time_frame>1 week before surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor reduction rate</measure>
    <time_frame>Within 1 month after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mediastinal lymph nodes clearance</measure>
    <time_frame>Within 1 month after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>Within 1 month after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>Within 1 month after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative mortality rate</measure>
    <time_frame>Within 1 month after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year overall survival</measure>
    <time_frame>5 years after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">590</enrollment>
  <condition>2-year Disease-Free Survival</condition>
  <arm_group>
    <arm_group_label>Oral Navelbine + Carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant therapy Patients with EGFR mutation will be recruited and treated with Navelbine + Carboplatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gefitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant therapy Patients with EGFR mutation will be recruited and treated with gefitinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Navelbine + Carboplatin</intervention_name>
    <description>The patient will be given Navelbine 60 mg/m2, p.o. day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v. day 1 of every cycle.After 2 cycle we will evaluate their clinical response.Then operable patients will have surgery.</description>
    <arm_group_label>Oral Navelbine + Carboplatin</arm_group_label>
    <other_name>Vinorelbine</other_name>
    <other_name>Carboplat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>The patient will be given Gefitinib 250mg,p.o.,q.d. for 8 weeks.After 8 weeks we evaluate their clinical response.Then operable patients will have surgery.</description>
    <arm_group_label>Gefitinib</arm_group_label>
    <other_name>Iressa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologic diagnosis of non small cell lung cancer, Stage Ⅱ-ⅢA before treatment

          -  EGFR Gene mutated

          -  ECOG 0-1

          -  liver, kidney and bone marrow are functional healthy，WBC&gt;4.0×109/L，PLT&gt;100×109/L
             Hb&gt;10g/dL;Cr&lt;1.8mg/dL，bilirubin＜1.5mg/dL，GPT&lt;1.5 upper limit of normal

          -  No vital systems dysfunction or malnutrition

          -  No other malignant diseases in 5 years（except non melanoma or Cervical carcinoma in
             situ）

          -  Have never accepted radiation therapy、overall chemotherapy or biotherapy

          -  Know the whole protocol，Voluntary participate and sign a consent form

        Exclusion Criteria:

          -  Tumor has violated the surrounding tissue organs（T4）

          -  Preoperative have evidence of distant metastasis including the contralateral
             mediastinal lymph nodes

          -  Arrhythmia need anti-arrhythmic treatment（except for β-blockers or
             digoxin），Symptomatic coronary artery disease and myocardial ischemia (myocardial
             infarction) in the past 6 months or more than NYHA class II congestive heart failure

          -  Adverse drug control severe hypertension

          -  Moderate to severe proteinuria

          -  History of HIV infection or activity of chronic hepatitis b or hepatitis c, or other
             active clinical severe infection

          -  Cachexy,organ function decompensation

          -  History of chest radiotherapy

          -  Not fully control the eye inflammation

          -  Epilepsy patients needed treatment（such as Steroids or antiepileptic cure）

          -  Interstitial pneumonia

          -  Drug abuse and medical, psychological or social conditions may interfere with the
             patients involved in the research or have an impact on the results of evaluation

          -  Known or suspected to study drug allergy or to give any drug allergies associated with
             this test

          -  Any unstable situation or may endanger the patient safety and compliance

          -  Fertility and pregnancy or lactation women, and have not been sufficient precautions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guowei Ma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guowei Ma, MD</last_name>
    <phone>13501546669</phone>
    <email>magw@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dongguan People's Hospital</name>
      <address>
        <city>Dongguan</city>
        <state>Guangdong</state>
        <zip>523000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianping Zhou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guowei Ma, MD</last_name>
      <email>magw@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Guowei Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Sixth Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jinming Zhao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maoming Affiliated Hospital of Southern Medical University</name>
      <address>
        <city>Maoming</city>
        <state>Guangdong</state>
        <zip>525000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiang Huang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guangsuo Wang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Guowei Ma</investigator_full_name>
    <investigator_title>Professor,Chief Physician</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

